News

Most recently, Dr Rioux was chief medical officer (CMO) of FerroKin Biosciences, a developer of iron chelator for treatment of anemias. Prior to that, Dr Rioux was CMO

Othera Pharmaceuticals, a specialty pharmaceutical company, has reported positive interim data from its Phase II trial of OT-551 in treating geographic atrophy, an advanced form of dry age-related

This patent infringement suit was originally filed in 2004 and relates to the use of lasers for endovenous ablation. CoolTouch will license the Navarro patent and pay royalties

Schering-Plough’s majority owned affiliate in India, Fulford India, has received approval for its Viraferonpeg, the pegylated interferon therapy in combination with Rebetol, for retreating adult patients with chronic

Keppra XR was approved by the FDA based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000mg of Keppra XR

The transaction includes a 10-year contract for Express Scripts to provide services to WellPoint following closing of the transaction. The transition to Express Scripts’s platform and products will

Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The

Mr Kanan succeeds Karen Miller who was recently promoted to vice president of strategy and corporate development. Mr Kanan will report to Rakesh Sachdev, vice president and CFO.

In this role, Dr George will be responsible for managing external relationships with cancer agencies, organizations and specialists around the world. Most recently, Dr George held the position